ImmunoGen kept at sector perform by RBC

RBC Capital Markets analyst Jason Kantor maintained ImmunoGen, Inc. at its sector perform, speculative risk, rating ahead of results from two phase 1 trials of huN901-DM1 and AVE9633. Kantor is encouraged by preliminary signs of efficacy for huN901-DM1 in multiple myeloma, but discouraged by a lack of efficacy of AVE9633 in leukemia. Shares of the Cambridge, Mass.-based pharmaceutical company were up 20 cents, or 4.44%, at $4.70. (Nasdaq: IMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.